Friday, July 10, 2026

pharma · Obesity, Overweight · Type 2 Diabetes

Eli Lilly and

Eli Lilly and trial registry — 107 ClinicalTrials.gov studies with program phase, status, and indication context.

Lilly Corporate Center, Indianapolis, Indiana 46285, US HQ
1876 Founded
55,860 Employees
EMA registrant Type
Company details
Status
Public
HQ
Lilly Corporate Center, Indianapolis, Indiana 46285, US
Founded
1876
Employees
55,860
Programs
107
Drugs
99
Patents
0
Intelligence · Clinical Trials

Eli Lilly and clinical trials

Registry index of 107 ClinicalTrials.gov studies linked to Eli Lilly and programs — each row shows trial ID, program name, phase, status, and indication.

Eli Lilly and trial registry — 107 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Eli Lilly and.

  1. I3Y-MC-JPEI — Phase 1

    Clinical update
  2. I3Y-MC-JPCE — Phase 1

    Clinical update
  3. LOXO-PIK-21001 — Phase 1

    Clinical update
  4. LOXO-LNC-24001 — Phase 1

    Clinical update
  5. LOXO-IDH-20001 — Phase 1

    Clinical update
  6. J6I-MC-OWAA — Phase 1

    Clinical update
  7. J6B-MC-YKAA — Phase 1

    Clinical update
  8. J5Q-OX-JRDA — Phase 1

    Clinical update

Trial registry

107 studies
  1. 2023-507678-42-00

    SELPERCATINIB, SELPERCATINIB

    Approved active small_molecule

    Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration;

    CTIS ↗
  2. 2024-511238-11-00

    LOXO-FRA-24001

    Phase 1 active other

    Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lung cancer, triple-negative breast cancer, pancreatic cancer and colorectal cancer.

    CTIS ↗
  3. 2024-516733-12-00

    J5Q-OX-JRDA

    Phase 1 active other

    Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor Metastatic Solid Tumor, PanKRAS.

    CTIS ↗
  4. 2025-522340-40-00

    I5T-MC-AACO

    Phase 3 active small_molecule

    Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders

    CTIS ↗